Last reviewed · How we verify
NCT03866395
Effects of Ivabradine on Residual Myocardial Ischemia After PCI
Phase 4 trial testing Ivabradine in Angina Pectoris, Stable in 28 participants. Completed in 7 March 2017.
7 March 2017
Quick facts
| Lead sponsor | Azienda Policlinico Umberto I |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 28 |
| Start date | 5 March 2015 |
| Primary completion | 7 March 2017 |
| Estimated completion | 7 March 2017 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Ivabradine (IVABRADINE) — full drug profile →
Conditions studied
- Angina Pectoris, Stable — all drugs for Angina Pectoris, Stable →
Sponsor
Azienda Policlinico Umberto I
Who can join
Adults 18 to 75, any sex, with Angina Pectoris, Stable. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized pharmacological study evaluating the effects of ivabradine in patients with residual angina after PCI. The role of ivabradine in patients with angina, without systolic dysfunction, is not yet clear. The investigators performed in all patients an echostress to evaluate the effects of therapy with ivabradine after 30 days in terms of exercise tolerance and diastolic function.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Ventricular voltage-gated ion channels: Detection, characteristics, mechanisms, and drug safety evaluation.
Chen L, He Y, Wang X, Ge J, et al · · 2021 · cited 12× · PMID 34709746 · DOI 10.1002/ctm2.530
Verify or expand the search:
- PubMed search for NCT03866395
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ivabradine
Trials testing the same drug.
- NCT07268170 — Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease · Phase 2, PHASE3 · enrolling by invitation
- NCT06312891 — Value of Heart Rate Lowering Therapy in Acute Myocarditis · unknown
- NCT06305806 — RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine) · Phase 2 · completed
- NCT06670690 — Comparison Between Atenolol,Propnalol and Ivabradine · NA · completed
- NCT05481177 — Ivabradine for Long-Term Effects of COVID-19 With POTS Cohort · Phase 4 · unknown
Other Azienda Policlinico Umberto I trials
Trials by the same sponsor.
- NCT06752135 — Node Positive Cervical Cancer Treated by Neoadjuvant Chemotherapy Plus Radical Surgery: a Single Center Experience · terminated
- NCT06770894 — DPP4-Inhibitors and Bone Metabolism in Diabetes · Phase 3 · completed
- NCT03579485 — An Observational Retrospective Database Analysis to Evaluate Raltegravir Based-regimens, Including NUC-sparing Regimens, · unknown
- NCT03875417 — Multidisciplinary Management of HCC in Elderly Patients · completed
- NCT03670992 — Surgical Treatment of Pancreatic RCC Metastases · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03866395 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Azienda Policlinico Umberto I
- Last refreshed: 7 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03866395.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing